DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Berenbaum F. et al.
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and
safety results from a 24-week randomised phase III study with a 24-week
follow-up period.
Ann Rheum Dis 2020;
79: 800-810
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.